News & Announcements
-
IQAI’s Sponsored Phase 1 Clinical Trial is Open
/**/ RNS Number : 2319E IQ-AI Limited 09 March 2022 FOR IMMEDIATE RELEASE IQ-AI LIMITED (“IQ-AI” or the “Company”) IQAI’s Sponsored Phase I Clinical Trial is Open Milwaukee – 9 March 2022: IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI) is pleased to announce that the sponsored Phase I clinical trial for oral gallium maltolate (GaM)
-
Imaging Biometrics Touts Position Paper for Monitoring High-Grade Glioma Treatment Response Panel of International Experts Deem MR DSC Perfusion as Most Clinically Validated
Milwaukee – 7 March 2022: Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce the publication of a review authored by International scientists about the use of advanced MRI techniques in Europe.
-
MD ANDERSON ADOPTS IB CLINIC FOR BRAIN TUMOR ANALYSIS
Milwaukee – 2 November 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms that have led to effective therapeutic strategies for brain tumor and other patients, today announced the University of Texas MD Anderson Cancer Center (Houston, TX) is the latest brain cancer center to purchase an annual
-
PUBLISHED NEUROSURGERY CASE REPORT UNDERSCORES CLINICAL VALUE OF IB SOFTWARE AFFILIATED HOSPITAL PURCHASES IB CLINIC FOR AUTOMATED ANALYSIS
Milwaukee – 1 October 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms announced a recent publication in Neurosurgery Open that illustrates the clinical impact of its neuro oncology software solutions for both neurosurgery and tissue diagnosis of high-grade brain tumors.
-
IQ-AI LIMITED AWARDED EU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
Milwaukee – 22 September 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer of medical image processing platforms that have led to effective therapeutic strategies that prolong survival and improve the quality of life in brain tumor and other patients, today announced it has been awarded a European Patent for “Multiparameter Perfusion Imaging